

7-8-04

PHA 4140.17 (SO3374/2)
PATENT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Mark Obukowicz
U.S. Application Serial No. 10/817,014
Filing Date April 2, 2004
Confirmation No. 2740
For SELECTIVE COX-2 INHIBITION FROM EDIBLE PLANT EXTRACTS
Examiner Michael V. Meller

Art Unit 1654

July 7, 2004

TO THE COMMISSIONER FOR PATENTS,

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

The references listed on the attached PTO/SB/08A, with the exception of reference 125, are of record in parent application Serial No. 09/737,892 and, therefore, in accordance with MPEP 609, are not being provided at this time. Reference 125 is attached.


*

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicant believes that it is being filed before the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. 1.97(c) is required. If Applicant is mistaken, and the mailing date of the first Office action on the merits precedes the filing of this Information Disclosure Statement, Applicant authorizes the Commissioner to charge the fee due under 37 C.F.R. 1.17(p) to Deposit Account No. 19-1345.

Respectfully submitted,

Timothy B. McBride, Reg. No. 47,781
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

TBM/sxm
* Enclosures
Mail Stop Amendment
Express Mail Label No. EV 432653945 US



PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	1	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,313,958		LaHann	02-02-1982
	2	4,613,591		Aburada et al.	09-23-1986
	3	4,618,495		Okuda et al.	10-21-1986
	4	4,767,626	A	Cheng	08-30-1998
	5	5,318,798	A	Uchida et al.	06-07-1994
	6	5,344,991	A	Reitz et al.	09-06-1994
	7	5,380,738	A	Norman et al.	01-10-1995
	8	5,393,790	A	Reitz et al.	02-28-1995
	9	5,447,719	A	Kamataki	09-15-1995
	10	5,466,823	A	Talley et al	11-14-1995
	11	5,521,207	A	Graneto	05-28-1996
	12	5,525,594	A	Gourvest et al.	06-11-1996
	13	5,633,272	A	Talley et al	05-27-1997
	14	5,753,688	A	Talley et al	05-19-1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	2	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	15	5,760,068	A	Talley et al	06-02-1998
	16	5,811,425	A	Woods et al	09-22-1998
	17	5,824,312	A	Unger et al.	10-20-1999
	18	5,932,598	A	Talley et al	08-03-1999
	19	6,217,875	B1	Okada et al.	04-17-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	20	EP	248215	B1	Popp et al.	12-09-1987	A
	21	GB	2168975	A	Janusz	07-02-1986	
	22	GB	2335599	A	Xia et al.	09-29-1999	
	23	WO	93/13055	A1	The Wellcome Foundation Limited	07-08-1993	
	24	WO	94/12165	A2	The Wellcome Foundation Limited	06-09-1994	
	25	WO	94/14780	A1	The Wellcome Foundation Limited	07-07-1994	
	26	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	27	WO	95/11231	A1	G.D. Searle & Co.	04-27-1995	
	28	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	3	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	29	WO	98/17292	A1	Sloth-Weidner	04-30-1998	
	30	WO	00/33824	A2	Nair et al.	06-15-2000	
	31	WO	00/40258	A1	Butters et al.	07-13-2000	
	32	WO	00/56348	A1	Corley et al.	09-28-2000	
	33	WO	00/72861	A	Armadillo Pharmaceuticals	12-07-2000	
	34	WO	00/74696	A1	Oxford Natural Products PLC	12-14-2000	
	35	WO	99/62532	A	Baylor College of Medicine	12-09-1999	
	36	JP	00 239169	A	Lotte Co. Ltd.	09-04-2000	A
	37	JP	56 020597		Takeda Chem Ind. Ltd.	02-26-1981	A
	38	JP	58 024523	A	Terumo kk	02-14-1983	A
	39	JP	59-106421	A	Tsumura Jiyuntendou:KK	06-20-1984	A
	40	JP	82 045412	A	Norin Suisansyo Chugoku Nogyo Shikenjo	09-24-1996	A
	41	JP	90 067360	A	Terumo Corp.	03-11-1997	A
	42	JP	2-188530	A	Tsurataka Tashiro	07-24-1990	A
	43	JP	4-005237	A	Nonogawa Shoji:KK	01-09-1992	A
	44	JP	4-208222	A	Tsumura & Co	07-29-1992	A
	45	JP	5-960	A	Kanebo LTD (JP)	12-23-1992	A
	46	JP	8-175956	A	KAO Corp	07-09-1996	A

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	4	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	47	JP	10-298098	A	Oryza Oil & Fat Chem (US)	04-17-2001	A
	48	JP	2000236835	A	Seika et al.	09-05-2000	A

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	49	ABAD, M.J., et al., "The Activity of Flavonoids Extracted from <i>Tanacetum microphyllum</i> DC. (Compositae) on Soybean Lipoxygenase and Prostaglandin Synthetase," 1995, Gen. Pharmacol., Vol. 26, No. 4, pp. 815-819.	
	50	ABAD, M.J., et al., "Anti-Inflammatory Activity of Hydroxyachillin, a Sesquiterpene Lactone from <i>Tanacetum microphyllum</i> ," 1994, Planta Med., Vol. 60, pp. 228-231.	
	51	ALANKO, J., et al., "Modulation of Arachidonic Acid Metabolism by Phenols: Relation to Their Structure and Antioxidant/Prooxidant properties," 1999, Free Radical Biology & Medicine, Vol. 26, Nos. 1/2, pp. 193-201.	
	52	AUERBACH, B.J., et al., "A Spectrophotometric Microtiter-Based Assay for the Detection of Hydroperoxy Derivatives of Linoleic Acid," 1992, Anal. Biochem., Vol. 201, No. 2, pp. 375-380.	
	53	BATRISTINI, B., et al., "COX-1 and COX-2: Toward the Development of More Selective NSAIDs," 1994, DN&P, Vol. 7, No. 8, pp. 501-512.	
	54	BINGÖL, F., et al., "A Review of Terrestrial Plants and Marine Organisms Having Antiinflammatory Activity," 1995, International Journal of Pharmacognosy, Vol. 33, No. 2, pp. 81-97.	
	55	CARTER, G.W., et al., "5-Lipoxygenase Inhibitory Activity of Zileuton," 1991, J. Pharmacol. and Exp. Ther., Vol. 256, No. 3, pp. 929-937.	
	56	CHANG, M., et al., "The Influence of Chinese Traditional Medicine on the Production and Activity of Interleukin 1(IL 1)," 1993, Chinese J. Microbiol. Immunol., Vol. 26, pp. 15-24.	A

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	5	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

57	CHOU, C.T., et al., "The Inhibitory Effect of Common Traditional Anti-Rheumatic Herb Formulas on Prostaglandin E and Interleukin 2 <i>in vitro</i> : A comparative Study with <i>Tripterygium wilfordii</i> ," 1998, J. Ethnopharmacol., Vol. 62, No. 2, pp. 167-171.	
58	COHEN, M.C., et al., "Cytokine Function," 1996, Am. J. Clin. Pathol., Vol. 105, No. 5, pp. 589-598.	
59	DANZ, H., et al., "Identification and Isolation of the Cyclooxygenase-2 Inhibitory Principle in <i>Isatis tinctoria</i> ," Planta Med., 2001, Vol. 67, pp. 411-416.	
60	DeWITT, D.L., et al., "The Differential Susceptibility of Prostaglandin Endoperoxide H Synthases-1 and -2 to Nonsteroidal Anti-Inflammatory Drugs: Aspirin Derivatives as Selective Inhibitors," 1995, Med. Chem. Res., Vol. 5, pp. 325-343.	
61	DUKE, J., "Clippings from my COX Box," 1998/1999, Journal of Medicinal Food, Vol. 1, No. 4, pp. 293-298.	
62	DUNSTAN, C.A., et al., "Evaluation of Some Samoan and Peruvian Medicinal Plants by Prostaglandin Biosynthesis and Rat Ear Oedema Assays," 1997, J. Ethnopharmacol., Vol. 57, No. 1, pp. 35-56.	
63	ELIAS, J.A., et al., "Synergistic Stimulation of Fibroblast Prostaglandin Production by Recombinant Interleukin 1 and Tumor Necrosis Factor," 1987, J. Immunol., Vol. 138, No. 11, pp. 3812-3816.	
64	EMMEL, E.A., et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," 1989, Science, Vol. 246, No. 1, pp. 1617-1620.	
65	GIERSE, J.K., et al., "Expression and Selective Inhibition of the Constitutive and Inducible Forms of Human Cyclo-Oxygenase," 1995, J. Biochem., Vol. 305 (Pt. 2), pp. 479-484.	
66	GIERSE, J.K., et al., "A Single Amino Acid Difference Between Cyclooxygenase-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors," 1996, J. Bio. Chem., Vol. 271, No. 26, pp. 15810-15814.	
67	HAQQI, T.M., et al., "Prevention of Collagen-Induced Arthritis in Mice by a Polyphenolic Fraction from Green Tea," 1999, Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 4524-4529.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	6	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	68	HENDERSON, B., et al., "Therapeutic Potential of Cytokine Manipulation," 1992, TIPS, Vol. 13, pp. 145-152.	
	69	JÄGER, A.K., et al., "Screening of Zulu Medicinal Plants for Prostaglandin-Synthesis Inhibitors," 1996, J. Ethnopharmacol, Vol. 52, No. 2, pp. 95-100.	
	70	JANG, M., et al., "Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes," 1997, Science, Vol. 275, No. 5297, pp. 218-220.	
	71	JUERGENS, U.R., et. al., "Inhibition of Cytokine Production and Arachidonic Acid Metabolism by Eucalyptol (1.8-Cineole) in Human Blood Monocytes <i>In vitro</i> ," 1998, Eur. J. Med. Res., Vol. 3, No. 11, pp. 508-510.	
	72	JUERGENS, U.R., et. al., "The Anti-Inflammatory Activity of L-Menthol Compared to Mint Oil in Human Monocytes In Vitro: A Novel Perspective For Its Therapeutic Use in Inflammatory Diseases," 1998, Eur. J. Med. Res., Vol. 3, No. 12, pp. 539-545.	
	73	KALGUTKAR et al., "Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2," 1998, Science, Vol. 280, pp. 1268-1270.	
	74	KALGUTKAR et al., "Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile Conversion of Nonsteroidal Antiinflammatory Drugs to Potent and Highly Selective Cox-2 Inhibitors," 2000, PNAS, Vol. 97, No. 2, pp. 925-930.	
	75	KARTTUNEN, J., et al., "Measurement of Ligand-induced Activation in Single Viable T Cells Using the <i>lacZ</i> Reporter Gene," 1991, PNAS, Vol. 88, pp. 3972-3976.	
	76	KASE, Y., et al., "Mechanisms by Which Hange-shashin-to Reduces Prostaglandin E2 Levels," 1998, Biol. Pharm. Bull., Vol. 21, No. 12, pp. 1277-1281.	
	77	KIM, H.P., et al., "Effects of Naturally-Occurring Flavonoids and Biflavonoids on Epidermal Cyclooxygenase and Lipoxygenase from Guinea Pigs," 1998, Prostaglandins Leukot. Essent. Fatty Acids, Vol. 58, No. 1, pp. 17-24.	
	78	KOIZUMI, T., et al., "Inhibitors of IL-2 Production and IL-2 Receptor Expression in Human Leukemic T-Cell Line, Jurkat," 1986, Cellular Immunology, Vol. 103, pp. 469-475.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	7	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	79	LANGLOIS, M., et al., "Synthese de nouvelles amidines bicycliques. 1. Derives de l'imidazole, du triazole-1,3,4 et du tetrazole," 1982, J. Heterocyclic Chem., Vol. 19, pp. 445-451.	
	80	LAVALLE, James B., "The COX-2 Connection: Natural Breakthrough Treatments for Arthritis, Alzheimer's, and Cancer," 2001, Healing Arts Press. (Table of Contents only)	
	81	LEE, S.H., et al., "α-Viniferin: A Prostaglandin H ₂ Synthase Inhibitor from Root of <i>Carex humilis</i> ," 1998, Planta Med., Vol. 64, pp. 204-207.	
	82	LENARDO, M.J., et al., "NF-κB: A Pleiotropic Mediator of Inducible and Tissue-Specific Gene Control," 1989, Cell, Vol. 58, pp. 227-229.	
	83	LINDSEY, K., et al., "Screening of Plants Used by Southern African Traditional Healers in the Treatment of Dysmenorrhoea for Prostaglandin-Synthesis Inhibitors and Uterine Relaxing Activity," 1999, Journal of Ethnopharmacology, Vol. 64, pp. 9-14.	
	84	LIU, J.H., et al., "Inhibitory Effects of <i>Angelica pubescens f. biserrata</i> on 5-Lipoxygenase and Cyclooxygenase," 1998, Planta Med., Vol. 64, pp. 525-529.	
	85	MALOFF, B.L., et al., "Development of an RIA-based Primary Screen for IL-1 Antagonists," 1988, Clin. Chim. Acta., Vol. 180, pp. 73-78.	
	86	MARNETT, L.J., et al., "Arachidonic Acid Oxygenation by COX-1 and COX-2," 1999, J. Bio. Chem., Vol. 274, No. 33, pp. 22903-22906.	
	87	McADAM, B.F., et al., "Systemic Biosynthesis of Prostacyclin by Cyclooxygenase (Cox)-2: The Human Pharmacology of a Selective Inhibitor of Cox-2," 1999, Proc. Nat. Acad. Sci. USA, Vol. 96, pp. 272-277.	
	88	MICALUART, P., et al., "Inhibitory Effects of Caffeic Acid Phenethyl Ester on the Activity and Expression of Cyclooxygenase-2 in Human Oral Epithelial Cells and in a Rat Model of Inflammation," 1999, Cancer Res., Vol. 59, pp. 2347-2352.	
	89	MIN, K.R., et al., "(-)-Epiatzelechin: Cyclooxygenase-1 Inhibitor and Anti-Inflammatory Agency from Aerial Parts of <i>Celastrus orbiculatus</i> ," 1999, Planta Med., Vol. 65, pp. 460-462.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	8	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	90	MITCHELL, J.A., et al., "Cyclooxygenase-2: Regulation and Relevance in Inflammation," 1995, Biochemical Pharmacology, Vol. 50, No. 10, pp. 1535-1542.	
	91	MOON, T.C., et al., "A New Class of Cox-2 Inhibitor, Rutaecarpine from <i>Evodia rutaecarpa</i> ," 1999, Inflamm. Res., Vol. 48, pp. 621-625.	
	92	NEWMARK, T.M., et al., "Beyond Aspirin: Nature's Answer to Arthritis, Cancer, and Alzheimer's Disease," 2000, Hohm Press, Prescott, AZ. (Table of Contents only)	
	93	NOREEN, Y., et al., "Development of a Radiochemical Cyclooxygenase-1 and -2 in Vitro Assay for Identification of Natural Products as Inhibitors of Prostaglandin Biosynthesis," 1998, J. Nat. Prod., Vol. 61, No. 1, pp. 2-7.	
	94	NOREEN, Y., et al., "Flavan-3-ols Isolated from Some Medicinal Plants Inhibiting COX-1 and COX-2 Catalysed Prostaglandin Biosynthesis," 1998, Planta Med., Vol. 64, pp. 520-524.	
	95	NOWLIN, D.M., et al., "A Novel Cyclic Pentapeptide Inhibits $\alpha 4\beta 1$ and $\alpha 5\beta 1$ Integrin-mediated Cell Adhesion," 1993, J. Biol. Chem., Vol. 268, No. 27, pp. 20352-20359.	
	96	O'NEILL, G.P., et al., "Overexpression of Human Prostaglandin G/H Synthase-1 and -2 by Recombinant Vaccinia Virus: Inhibition by Nonsteroidal Anti-Inflammatory Drugs and Biosynthesis of 15-Hydroxyeicosatetraenoic Acid," 1994, Mole. Pharmacol., Vol. 45, pp. 245-254.	
	97	PENNISI, E., "Building a Better Aspirin," 1998, Science, Vol. 280, pp. 1191-1192.	
	98	REDDY, A.Ch., et al., "Studies on Anti-Inflammatory Activity of Spice Principles and Dietary n-3 Polyunsaturated Fatty Acids on Carrageenan-Induced Inflammation in Rats," 1994, Ann. Nutr. Metab., Vol. 38, No. 6, pp. 349-358.	
	99	REDDY, C.M., et al., "Selective Inhibition of Cyclooxygenase-2 by C-Phycocyanin, a Biliprotein from <i>Spirulina platensis</i> ," 2000, Biochem. Biophys. Res. Commun., Vol. 277, No. 3, pp. 599-603.	
	100	RESCH, M., et al., "5-Lipoxygenase and Cyclooxygenase-1 Inhibitory Active Compounds from <i>Atractylodes lancea</i> ," 1998, J. Nat. Prod., Vol. 61, No. 3, pp. 347-350.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	9	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	101	RESCH, M., et al., "Further Phenols and Polyacetylenes from the Rhizomes of <i>Atractylodes lancea</i> and their Anti-Inflammatory Activity," 2001, <i>Planta Med.</i> , Vol. 67, pp. 437-442.	
	102	RINGBOM, T., et al., "COX-2 Inhibitory Effects of Naturally Occurring and Modified Fatty Acids," 2001, <i>J. Nat. Prod.</i> , Vol. 64, No. 6, pp. 745-749.	
	103	RINGBOM, T., et al., "Ursolic Acid from <i>Plantago major</i> , a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin Biosynthesis," 1998, <i>J. Nat. Prod.</i> , Vol. 61, No. 10, pp. 1212-1215.	
	104	RUBIN, P., et al., "Pharmacokinetics, Safety, and Ability to Diminish Leukotriene Synthesis by Zileuton, an Inhibitor of 5-Lipoxygenase," 1991, <i>Agents Actions Suppl.</i> , Vol. 35, pp. 103-116 (abstract only).	
	105	SEGURA, L., et al., "Anti-Inflammatory Activity of Dichloromethane Extract of <i>Heterotheca inuloides</i> in Vivo and in Vitro," 2000, <i>Planta Med.</i> , Vol. 66, pp. 553-555.	
	106	STOLTENBORG, J.K., et al., "A Fluorescent Cellular Adhesion Assay Using Insect Cell Produced Human VCAM1," 1994, <i>J. Immunological Methods</i> , Vol. 175, No. 1, pp. 59-68.	
	107	SUBBARAMAIIH, K., et al., "Resveratrol Inhibits Cyclooxygenase-2 Transcription and Activity in Phorbol Ester-treated Human Mammary Epithelial Cells," 1998, <i>J. Biol. Chem.</i> , Vol. 273, No. 34, pp. 21875-21882.	
	108	SUBBARAMAIIH, K., et al., "Resveratrol Inhibits Cyclooxygenase-2 Transcription in Human Mammary Epithelial Cells," 1999, <i>Ann. N.Y. Acad. Sci.</i> , Vol. 889, pp. 214-223.	
	109	SUBBARAMAIIH, K., et al., "Resveratrol Inhibits the Expression of Cyclooxygenase-2 in Human Mammary and Oral Epithelial Cells," 1998, <i>Pharm. Biol.</i> , Vol. 36, pp. 35-43.	
	110	SUBBARAMAIAH, K., et al., "Ursolic Acid Inhibits Cyclooxygenase-2 Transcription in Human Mammary Epithelial Cells," 2000, <i>Cancer Res.</i> , Vol. 60, Supplement, pp. 2399-2404.	
	111	TAYLOR, J.L.S., et al., "COX-1 Inhibitory Activity in Extracts from <i>Eucomis</i> L'herit. Species," 2001, <i>J. Ethnopharmacol.</i> , Vol. 75, Nos. 2-3, pp. 257-265.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	10	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	112	TUNÓN, H., et al., "Evaluation of Anti-inflammatory Activity of Some Swedish Medicinal Plants. Inhibition of Prostaglandin Biosynthesis and PAF-induced Exocytosis," 1995, J. Ethnopharmacol., Vol. 48, pp. 61-76.	
	113	TYLER, V. E., "Phytomedicines: Back to the Future," 1999, J. Nat. Prod., Vol. 62, No. 11, pp. 1589-1592.	
	114	WANG, H., et al., "Antioxidant and Antiinflammatory Activities of Anthocyanins and Their Aglycon, Cyanidin, from Tart Cherries," 1999, J. Nat. Prod., Vol. 62, No. 2, pp. 294- 296.	
	115	WELKER, P., et al., "Glucocorticoid-Induced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells," 1996, International Arch. of Allergy and Immunology, Vol. 109, pp. 110-115.	
	116	WHITEHOUSE, M.W., et al., "Over the Counter (OTC) Oral Remedies for Arthritis and Rheumatism: How Effective Are They?" 1999, Inflammopharmacology, Vol. 7, No. 2, pp. 89-105.	
	117	WILLIAMS, C.A, et al., "The Flavonoids of <i>Tanacetum parthenium</i> and <i>T. vulgare</i> and their Anti-inflammatory Properties," 1999, Phytochemistry, Vol. 51, No. 3, pp. 417-423.	
	118	YOU, K.M., et al., "Inhibition of Cyclooxygenase/Lipoxygenase from Human Platelets by Polyhydroxylated/Methoxylated Flavonoids Isolated from Medicinal Plants," 1999, Arch. Pharm. Res., Vol. 22, No. 1, pp. 18-24.	
	119	ZENG, X., et al, "Studies on Anti-inflammatory and Analgesic Effects of <i>Dracaena cochinchinensis</i> ," 1999, Zhongguo Zhongyao Zazhi, Vol. 24 No. 3, pp. 171-173.	A
	120	ZHANG, F., et al., "Curcumin Inhibits Cyclooxygenase-2 Transcription in Bile Acid- and Phorbol Ester-treated Human Gastrointestinal Epithelial Cells," 1999, Carcinogenesis, Vol. 20, No. 3, pp. 445-451.	
	121	ZSCHOCKE, S., et al., "5-Lipoxygenase and Cyclooxygenase Inhibitory Active Constituents from <i>Qianghuo (Notopterygium incisum)</i> ," 1997, Planta Med., Vol. 63, pp. 203-206.	
	122	Hawley's Condensed Chemical Dictionary, 1997, 13th Edition, Revised by Lewis, p. 736.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,014
				Filing Date	April 2, 2004
				Confirmation Number	1654
				First Named Inventor	M. Obukowicz
				Group Art Unit	1654
				Examiner Name	TBD
Sheet	11	of	11	Attorney Docket No.	PHA 4140.17 (SO3374/2)

	123	International Search Report for PCT/US01/48912 dated 10/22/03; 14 pgs.	
	124	International Search Report for PCT/US01/48650 dated 10/22/03; 16 pgs.	
	125	Nexrutine™ brochure for Remedief™, "Triple Action Pain Management with Natural Cox-2 Inhibitor," Undated.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.